Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

Good morning! This is Fly Charts, the daily charts-only email from Gadfly; sign up here. From MS drug outrage to Calpine's less-than-energetic buyout, here are four charts that tell you what you need to know in business. 

Rocky Week
That increasingly loud hiss you're hearing? It's the air being let out of the Trump bubble.
Source: Bloomberg
Intraday times are displayed in ET.
The Case
MS medicines that seem magnetically drawn toward the same ever-higher price point are the next focus of congressional ire.
Source: House Oversight committee
AWP estimates from congressional letter
Hope You Bought Recently
Longer-term Calpine holders might be grouchy about a $15.25 buyout, but it's arguably about the best they could hope for.
Source: Bloomberg
Big Gap
People love ETFs because they think they're cheap. But there can be substantial hidden costs.
Source: Bloomberg
Note: Weekly returns

And don't miss Andrea Felsted on Britain's restaurant gorge: "Since the U.K. emerged from recession, much of the extra income in consumer pockets has gone on eating out rather than on buying stuff. With inflation outstripping wage growth, that spending on so-called 'experiences' might be reined in, too. Not a happy prospect for restaurant chains in the crowded 'casual-dining' market, nor the private equity groups that back many of them."

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

To contact the author of this story:
Max Nisen in New York at

To contact the editor responsible for this story:
Daniel Niemi at